Moleculin reports promising preliminary phase II
Moleculin Biotech reported interim blinded Part A data from its MIRACLE Phase II/III trial of Annamycin plus cytarabine (AnnAraC) in relapsed or refractory AML. In 62 evaluable patients, CR was 24% and CRc 37%. Among 30 prior venetoclax-failure patients, results were in a harder-to-treat group. Part A has 74/90 enrolled, completion expected by Sep 2026, unblinded results Dec 2026-Feb 2027.
How this was made
The 30-second read
Why it matters
The newest disclosed facts are interim blinded efficacy metrics (CR 24%, CRc 37% in 62 evaluable patients) and subgroup context (30 patients previously failed venetoclax-based therapy), alongside continued monitoring for cardiotoxicity and Part A enrollment progress (74 of 90).
Market read
Traders may reprice the probability of success for Annamycin in r/r AML based on interim response rates and subgroup performance, while recognizing the results remain blinded.
What to watch
The article cites cardiotoxicity absence based on ejection fractions and adverse events, but provides no event rates, grade distribution, or comparative safety versus control.
Background
Moleculin Biotech is running the pivotal Phase II/III MIRACLE trial evaluating Annamycin (annamycin) plus cytarabine (AnnAraC) in adults with relapsed or refractory AML, with Part A comparing two dosing regimens against cytarabine plus placebo.
Ticker impact
Moleculin Biotech reported interim blinded Part A Phase II/III MIRACLE data for Annamycin plus cytarabine, including CR 24% and CRc 37% in 62 evaluable patients.
Moderate positive bias into the next data unblinding window (Dec 2026 to Feb 2027), with volatility around trial milestones.
The article discloses specific interim response rates and enrollment progress, but remains blinded and does not provide unblinded arm separation or safety event rates.
Market effects
Adds incremental read-through for AML salvage regimens combining novel agents with cytarabine, potentially supporting sentiment toward similar clinical-stage hematology programs.
No direct regional macro linkage; trial sites span US and EU but the catalyst is company-specific.
Limited global spillover beyond biotech/hematology investors tracking r/r AML trial outcomes.
Counterpoint
Blinded interim results can overstate confidence because control-arm inclusion and lack of unblinded arm separation make it hard to judge true incremental benefit.
Key entities
- companyMoleculin Biotech, Inc.
Clinical-stage pharmaceutical company reporting interim blinded Part A data from the MIRACLE Phase II/III trial for Annamycin plus cytarabine in r/r AML.
- clinical_programMIRACLE trial
Pivotal Phase II/III study evaluating Annamycin plus cytarabine (AnnAraC) versus cytarabine plus placebo, with Part A interim blinded analysis.
- drugAnnamycin (AnnAraC)
Investigational agent combined with cytarabine; the article claims no evidence of cardiotoxicity so far.
